Abstract
Canrenone is the main active metabolite1 of the diuretic and antihypertensive drugs spironolactone and canrenoate-K, and competes with aldosterone for a common cytosolic receptor in distal and collecting tubules of the nephron.2 In addition it has recently been demonstrated that canrenone in vitro may directly interfere with ouabain-sensitive Na+,K+ pump (Na+,K+ adenosine triphosphatase), acting as a partial agonist at the digitalis receptor site. 3,4 Moreover Garay et al.4 showed that canrenone is able to restimulate in vitro the Na+,K+ pump of human red blood cells (RBC) blocked by high concentrations of ouabain.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
W. Sadéé M. Dagcioglu, and R. J. Schroder, Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans, Pharmacol. Exp. Ther. 185: 686–695 (1973).
D. Marver and J. P. Kokko, Renal target sites and the mechanism of action of aldosterone. Min. Electrolyte Metab. 9: 1–18 (1983).
P. Finotti and P. Palatini, Canrenone as a partial agonist at the digitalis receptor site of sodium potassium activated adenosine triphosphatase, J. Pharmacol. Exp. Ther. 217: 784–790 (1981).
R. P. Garay, J. Diez, C. Nazaret, G. Dagher, and J. P. Abitbol, The interaction of canrenone with the Na+,K+ pump in human red blood cells, Naunyn-Schmiedeberg’s Arch. Pharmacol. 329: 311–315 (1985).
L. G. Welt, G. R. Sachs, J. J. Macmanus, An ion transport defect in erythrocytes from uremic patients. Trans. Assoc. Am. Phys. 77: 169–181 (1964).
L. G. Welt, E. K. M. Smith, M. J. Dunn, A. Szerwinski, H. Proctor, C. Cole, J. W. Balfe and H. J. Gitelman, Membrane transport defect: the sick cell. Trans, Assoc, Am, Phys, 30: 217–226 (1967).
A. P. Quintanilla, Alteration of Na,K pump in the uremic state. Int. J. Artif. Organs 10: 337–442 (1988).
H. Izumo, S. Izumo, M. DeLuise and J. Flier, Erythrocyte pump in uremia. Acute correction of transport defect by hemodialysis, J. Clin. Invest, 74: 581–588 (1984).
F. Quarello, R. Boero, C. Guarena, C. Rosati, M.C. Deabate, T. Fidelio and G. Piccoli, Red blood cell Na+,K+ pump activity in patients on hemofiltration. Blood Purif. 2: 130–134 (1984).
C. H. Cole, J. W. Balfe and C. G. Welt, Induction of an ouabain sensitive ATPase defect by uremic plasma. Trans. Assoc. Am. Phys. 81: 213–221 (1968).
H. J. Kramer, J. Pennig, D. Klingmüller, J. Kipnowski, K. Glänzer and R. Düsing, Digoxin-like immunoreacting substance(s) in the serum of patients with chronic uremia. Nephron 40: 297–302 (1985).
J. H. Acosta, Hypertension in chronic renal failure. Kidney Int. 22: 702–712 (1982).
M. P. Blaustein, Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. Am. J. Physiol. 232: C165-C173 (1977).
J. Fernandez, J. R. Oster and G. O. Perez, Impaired extrarenal disposal of an acute oral potassium load in patients with end stage renal disease on chronic hemodialysis. Min. Electrolyte Metail. 12: 125–129 (1986).
V. Buckalew and K. Gruber, Natiuretic hormone, in: “The Kidney in Liver disease”, M. Epstein, ed., Elsevier Biomedical, New York (1983), p. 479–499.
J. M. Krzezinsky and G. Rorive, (letter), N. Engl. J. Med. 309: 987–988 (1983).
F. Quarello, R. Boero, C. Guarena, C. Rosati, G. Giraudo, F. Giacchino and G. Piccoli, Acute effects of hemodialysis on erythrocyte sodium fluxes in uremic patients. Nephron 41: 22–25 (1985).
G. Deray, M. G. Pernollet, M. A. Devynck, J. Zingraff, A. Touam, J. Rosenfeld and P. Meyer, Plasma digitalis-like activity in essential hypertension or end-stage renal disease. Hypertension 8: 632–638 (1986).
R. Boero, F. Quarello, C. Guarena, C. Rosati and G. Piccoli, Effects of an intravenous saline load on erythrocyte sodium transport in normal human subjects, Clin. Sci. 69: 709–712 (1985).
F. Quarello, R. Boero, C. Guarena, M. C. Deabate, M. C. Forneris, C. Rosati, B. Rolando and G. Piccoli, II canrenone previene 1’inibizione della Na+,K+ pompa indotta dall’ espansione del volume extracellulare, ia: “Nefrologia Dialisi Trapianto”, C. Giordano and N. DeSanto, eds., Wichtig, Milano (1986), p. 431–434.
R. Boero, C. Guarena, M. C. Deabate, B. Rolando, C. Rosati, F. Quarello and G. Piccoli, Erythrocyte Na+,K+ pump inhibition following saline infusion in essential hypertensive subjects: effects of canrenone administration. Int. J. Cardiology (in press).
G. Pati, E. Niutta, M. G. Tripodi, C. Barlassina, D. Cusi and G. Bianchi, Inibizione dell’azione delle sostanze endogene ad attivitè ouabaino-simile da parte del canrenoato di K nell’ ipertensione arteriosa essenziale, in: “Atti XXVI Congresso Nazionale Societa Italiana di Nefrologia”, F. Mastrangelo, S. Rizzelli, V. De Blasi, L. Alfonso and D. Brancaccio, eds. Wichtig, Milano (1985), p. 247–250.
H. E. de Wardener and G. A. MacGregor, The natriuretic hormone and essential hypertension. Lancet 26: 1450–1454 (1982).
M. De Mendonca, M. L. Grichois, M. G. Pernollet, B. Thorman, P. Meyer, M. A. Devynck and R. Garay, Hypotensive action of canrenone in a model of hypertension where ouabain-like factors are present, J. Hypertension 3 (suppl. 3): 73–75 (1985).
M. L. Grichois, M. De Mendonca, I. Wauquier, M. G. Pernollet, B. Thorman, M. A. Devynck, P. Meyer and R. P. Garay, La canrénone: un antihypertenseur efficace dans le modèle expérimental d’hypertension Où le transport actif du sodium est diminué. Arch. Mai. Coeur 6: 875–878 (1986).
J. Brod, J. Shaeffer, H. Hengtenberg and T. Kleinschmidt, Investig ations on the Na+,K+ pump in erythrocytes of patients with renal hypertension, Clin. Sci. 66: 351–355 (1984).
R. Boero, C. Guarena, I. M. Berto, M. C. Deabate, C. Rosati, F. Quarello and G. Piccoli, Erythrocyte pump activity and arterial hypertension in uremic dialyzed patients (submitted).
P. Salvati, F. Vaghi, M. Colombo and G. Bianchi, The interaction of canrenone with the Na,K pump in isolated rabbit renal arteries, in: “Abs. Xth Int. Congr. Nephrol.”, London (1987), p. 300.
S. Laurent, P. Hannaert, X. Girard, M. Safar and R. P. Garay. Chronic treatment with canrenone in essential hypertensive patients potentiates the acute pressor effect of ouabain, J. Hypertension 5: S173-S175 (1987).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Plenum Press, New York
About this chapter
Cite this chapter
Quarello, F. et al. (1989). Effects of Canrenone on Na+, K+ ATPase Activity, Arterial Pressure and Plasma Potassium Concentration in Uremic Hemodialyzed Patients. In: Amerio, A., Coratelli, P., Campese, V.M., Massry, S.G. (eds) Drugs, Systemic Diseases, and the Kidney. Advances in Experimental Medicine and Biology, vol 252. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8953-8_38
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8953-8_38
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8955-2
Online ISBN: 978-1-4684-8953-8
eBook Packages: Springer Book Archive